Skip to main content
Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Risk Associated with Bee Venom Therapy: A Systematic Review and Meta-Analysis

  • Jeong Hwan Park,

    Affiliation Acupuncture, Moxibustion and Meridian Research Group, Korean Institute of Oriental Medicine, Daejeon, South Korea

  • Bo Kyung Yim,

    Affiliation Division of Cardiovascular and Rare Diseases, Center for Biomedical Science, National Institute of Health, Cheongju, Chungcheongbuk-do, South Korea

  • Jun-Hwan Lee,

    Affiliation Acupuncture, Moxibustion and Meridian Research Group, Korean Institute of Oriental Medicine, Daejeon, South Korea

  • Sanghun Lee,

    Affiliation Acupuncture, Moxibustion and Meridian Research Group, Korean Institute of Oriental Medicine, Daejeon, South Korea

  • Tae-Hun Kim

    Affiliation Korean Medicine Clinical Trial Center, Korean Medicine Hospital, Kyung Hee University, Seoul, South Korea



The safety of bee venom as a therapeutic compound has been extensively studied, resulting in the identification of potential adverse events, which range from trivial skin reactions that usually resolve over several days to life-threating severe immunological responses such as anaphylaxis. In this systematic review, we provide a summary of the types and prevalence of adverse events associated with bee venom therapy.


We searched the literature using 12 databases from their inception to June 2014, without language restrictions. We included all types of clinical studies in which bee venom was used as a key intervention and adverse events that may have been causally related to bee venom therapy were reported.


A total of 145 studies, including 20 randomized controlled trials, 79 audits and cohort studies, 33 single-case studies, and 13 case series, were evaluated in this review. The median frequency of patients who experienced adverse events related to venom immunotherapy was 28.87% (interquartile range, 14.57–39.74) in the audit studies. Compared with normal saline injection, bee venom acupuncture showed a 261% increased relative risk for the occurrence of adverse events (relative risk, 3.61; 95% confidence interval, 2.10 to 6.20) in the randomized controlled trials, which might be overestimated or underestimated owing to the poor reporting quality of the included studies.


Adverse events related to bee venom therapy are frequent; therefore, practitioners of bee venom therapy should be cautious when applying it in daily clinical practice, and the practitioner’s education and qualifications regarding the use of bee venom therapy should be ensured.


Bee venom is one of the most commonly encountered animal venoms and consists of various chemical agents that induce allergic reactions in the human body [1]. Bee venom therapy (BVT), in which bee venom is used for medicinal purposes, is available worldwide, but is primarily utilized in Asia, Eastern Europe, and South America [2]. The diverse therapeutic applications of BVT include various musculoskeletal conditions, such as arthritis and rheumatism, chronic recalcitrant neuralgia, arthralgia, and immune-related diseases. BVT is also used to desensitize patients to bee stings and thus inhibit allergic reactions [3] [4] [5].

Although the therapeutic utility of bee venom has been demonstrated, its safety profile is an important limiting consideration, because immune responses to BVT can range from trivial skin reactions that resolve over several days to life-threatening responses such as anaphylaxis [6] [7]. In a recent survey, the incidence of systematic reactions (SRs) in patients who received venom and inhaled-allergen subcutaneous immunotherapy was 13.60%, whereas the prevalence of SRs in patients that received bee venom immunotherapy (VIT) was 28.72% [8]. In another survey, 12.13% patients who received VIT experienced SRs (an average of 1.91 SR events per subject), suggesting that serious adverse events (SAEs) due to BVT are quite common [9].

The most significant issue related to the AEs of BVT is that the occurrence of SAEs is unpredictable. It is therefore necessary to determine the prevalence and nature of AEs related to various types of BVT, so that bee venom can be used safely in clinical practice. The aim of this systematic review was to provide summary information regarding the types of AEs related to BVT and their prevalence in treated patients.


Study selection

Types of studies.

All types of clinical studies, including randomized controlled trials (RCTs) and randomized crossover trials, as well as observational studies, including cohort studies, case-control studies, case series, and case studies, were included in this study.

Types of participants.

The subjects of the studies evaluated in this review included adults and pediatric patients, and the selection was not limited to studies of patients with specific diseases. Regardless of a patient’s condition and disease status, studies were included if bee venom was used as a key intervention, and AEs that may have been causally related to BVT were reported.

Types of interventions.

In this review, we included studies of bee sting acupuncture (BSA), a subcutaneous or intramuscular injection of bee venom for the purpose of acupoint stimulation (bee venom acupuncture [BVA], sweet bee venom [SBV]), and dried honeybee venom (apitoxin injections), as well as subcutaneous VIT for desensitization of venom immune reactions. BSA, BVA, SBV, and apitoxin injections usually involve the use of venom derived from bees (family Apidae), whereas VIT generally involves the use of venom from bees (family Apidae) and wasps (family Vespidae) concomitantly. Therefore, we included all types of venom therapy including both bee and wasp venoms. We also reviewed studies where bee venom was used alone or in combination with other treatments. However, studies describing bee stings resulting from random encounters (e.g., during resting or by attack), sting challenge tests, sublingual VIT, and irrelevant venom types were excluded from this study. We included RCTs comparing BVT with no treatment, normal saline injections, and conventional medications for relative risk assessment. Trials in which different types of BVT were compared with each other were excluded.

Types of outcome measures.

The major aim of this review was to identify the frequency and types of AEs related to BVT. In case studies and case review series, the type of AE was classified into 1 of 3 categories: SR, skin problem (SP), and other (nonspecific reaction, symptom, or sign that was not an SR or SP). If an SR occurred as an AE, it was classified into 1 of 5 categories based on the Mueller classification (grade I, grade II, grade III, and grade IV) [10]. The causal relationship between BVT and AEs was also assessed in each study according to the WHO-UMC causality scale [11]. AEs were scored as certain when they clearly occurred after BVT, disappeared after withdrawal, and could not be explained by other diseases or treatments. AEs were scored as probable when the timing of the AEs and BVT indicated that they were most likely related, they disappeared as a probable result of the discontinuation of BVT, and the events were not induced by other diseases or treatment. AEs were scored as possible when they occurred after BVT treatment but no information was available on the relationship between their disappearance and the withdrawal of BVT and when they could potentially be explained by other diseases or treatments. In addition, AEs were scored as unlikely when the event and the BVT had an improbable causal relationship. AEs were scored as conditional/unclassified when the event occurred but more data were necessary for a conclusion to be reached. Finally, AEs were scored as unassessable/unclassifiable when they could not be evaluated properly owing to insufficient and/or contradictory information [12].

In audits and cohort studies, AE types were divided into SR, large local reaction (LLR), local reaction (LR), and other (nonspecific reaction, symptom, or sign that was not an SR, LLR, or LR). An LLR was defined as swelling exceeding 10 cm in diameter and lasting longer than 24 h, and an LR was defined as local pruritus, edema, or erythema [13]. Finally, the prevalence of AEs related to BVT was assessed through observational studies, including audits and cohort studies.

Data sources

The following 12 databases were searched: PubMed, EMBASE, the Cochrane Library, CINAHL, China National Knowledge Infrastructure (CNKI), Wanfang (China), Weipu (China), KoreaMED, the Korean Medical Database (KMBASE), the Korean Studies Information Service System (KISS), National Discovery for Science Leaders (NDSL) (Korea), and the Oriental Medicine Advanced Searching Integrated System (OASIS) (Korea). Bibliographic references in relevant publications (Journal of Pharmacopuncture) were manually searched to avoid missing eligible articles. The References sections of reviews on AEs of BVT were searched manually, and articles published through June 2014 were included. The search terms consisted of two parts: “BVT” (e.g., bee sting, apitoxin, or venom immunotherapy) and “adverse events” (e.g., adverse reaction, side effects, risk, or safe). The search strategy was modified appropriately according to the databases. The detailed search strategies for PubMed, China National Knowledge Infrastructure (CNKI), Wanfang (China), Weipu (China), KoreaMED, the Korean Medical Database (KMBASE), the Korean Studies Information Service System (KISS), National Discovery for Science Leaders (NDSL) (Korea), and the Oriental Medicine Advanced Searching Integrated System (OASIS) (Korea) are presented in the Supporting Information.

Data collection and analysis

Study selection.

Two independent reviewers (JHP and BKY) screened the articles for inclusion by title and abstract. If disagreements regarding the selection of a study could not be resolved through discussion, the final decision was made by the arbiter (THK).

Data extraction and management.

One reviewer (JHP) read the full text of the articles selected for review and extracted the data using a standard data extraction form. Another reviewer (BKY) rechecked the data to ensure that it had been extracted appropriately. Any disagreement among the reviewers was resolved by discussion or by the arbiter (THK).

Quality assessment of AEs in RCTs.

To evaluate the quality of the detection and reporting of the AEs in the included RCTs, 7 items were assessed according to the CONSORT recommendations for harm data: (1) mention of AEs in the title or abstract, (2) mention of BVT-related AEs in the introduction, (3) predefined definition of AEs related to BVT, (4) collection or monitoring method for AEs, (5) mention of the method for analyzing and presenting AEs, (6) mention of any patients who dropped out of the study owing to AEs, and (7) mention of the specific denominator for the analysis of AEs [14] [15]. The quality of each item was judged as good, moderate, bad, or not reported [12]. The quality of a study was scored as good if each item was reported clearly in the manuscript or in the registered protocol. If each item was reported, but not in detail, the methodological quality was scored as moderate. The quality of a study was scored as bad when any of the items were not appropriately reported. If an item was not described at all, it was recorded as not reported.

Statistical analysis

A meta-analysis of the RCTs was conducted if the incidence of AEs was clearly reported and the relative risk of AEs could be assessed because of similar study designs and intervention methods, including BVT types and control interventions, with minimal clinical heterogeneity. The relative risk of BVT and control interventions was assessed, and effects were calculated using Revman 5.2 software (


Through electronic and manual searching, 8,108 potentially relevant articles were identified, including 5,504 records from PubMed, EMBASE, the Cochrane Library, and CINAHL; 468 records from the Chinese databases; and 2,136 records from the Korean databases, from which 2,118 duplicate records were removed. Through a screening process involving the use of the titles and abstracts of identified records, we excluded 5,699 records that did not meet the inclusion criteria. The remaining 291 articles were reviewed for eligibility, and 146 articles were excluded, including experimental studies (32), reviews (57), surveys (3), studies without description of the assessment of AEs (43), and studies without relevant intervention or comparison groups (11). Finally, 145 studies, including 20 RCTs, 79 audits and cohort studies, 33 single-case studies, and 13 case series, were included in the review (Fig 1).

Case studies and case series

Thirty-three single-case studies and 13 case series were identified as described in Table 1 [2,7,1659]. A total of 69 individual isolated cases were reported in 46 papers. Incidents were reported in 11 countries: Korea (37 cases), China (10 cases), the United States (7 cases), France (6 cases), Germany (2 cases), Turkey (2 cases), Canada (1 case), Italy (1 case), Russia (1 case), Saudi Arabia (1 case), and the Slovak Republic (1 case). The reported BVT methods included BSA (29), BVA (21), and VIT (19). Among the 69 AE cases, 58 cases were related to BVT, 6 cases were related to wasp venom treatment, and 5 cases were related to treatment with a mixture of bee venom and wasp venom. Among the 58 AE cases related to treatment with bee venom only, 30 SRs, 23 SPs, and 5 other cases, including cough; headache; uremia; anorexia; discoloration of the sclera; jaundice; painful cyclic uterine contractions; severe pain affecting the left shoulder, chest wall, and left arm; and muscular weakness in the left arm and hand, were reported. The 30 SRs related to treatment with bee venom only were classified as grade I (5 cases), grade II (10 cases), grade III (14 cases), and grade IV (1 case). The severity of the AEs related to BVT only were reported as moderate (34 cases) or severe (24 cases), and the causality was deemed to be probable for 49 cases and possible for 9 cases. Most practitioners were qualified practitioners (30 cases), and 4 patients were treated by unqualified personal with no medical training or licensure regarding BSA. One patient died after treatment by an unqualified BSA practitioner. In 23 cases, there was no description of the practitioner. A pre-treatment skin test for venom allergies was reported in only 10 cases, and it was almost always performed prior to VIT, whereas in most cases of BSA and BVA, it was not reported whether or not this test was conducted.

Table 1. Case studies and case series on adverse events associated with bee venom therapy.

Audits and cohort studies

AEs were also reported in 79 mainly retrospective audit studies that aimed to assess the safety of BVT (Table 2) [60138]. These studies were chiefly observational and included case-controlled and cohort studies. VIT (63 studies) was the most commonly used BVT method, followed by BSA (9 studies) and BVA (7 studies). The treatment protocol for VITs included conventional VIT, cluster VIT, rush VIT, ultra-rush VIT, specific immunotherapy, and rush-specific immunotherapy. Eleven studies were conducted in Spain, 10 studies were conducted in China, 8 studies were conducted in Italy and the United States, 6 studies were conducted in Germany, 5 studies were conducted in France, Korea, and Switzerland, and 21 studies were conducted in 18 other countries. The prevalence of AEs ranged from 0.00% [60] [117] [118] [134] up to 90.63% [109]. In the 46 VIT studies, the median incidence (number of patients with AEs/number of patients in all cases, %) of AEs was 28.87% (interquartile range [IQR], 14.57–39.74%), and the AE types included SR (50.37%), LR (35.80%), LLR (9.99%), and other (3.85%; blood pressure elevation, moderate hypotension, rhinitis, asthenia or headache, visual disorders and vertigo, transient dyspnea, proteinuria with microscopic hematuria, generalized pruritus without skin lesions or other signs, and not reported).

Table 2. Audits and cohort studies on the adverse events of bee venom therapy


RCTs and randomized crossover trials

Eighteen RCTs and 2 randomized crossover trials were included in this review (Table 3) [139158]. One-hundred and forty-eight AEs related to BVT were reported in 397 participants. Seventeen patients ended their study participation owing to BVT-related AEs. For the BSA and BVA studies, all of the participants who were negative for skin allergy tests were included in the studies. With regard to the quality of the reporting of AEs, more than half of the items in the CONSORT AE reporting guidelines were not reported (52.14%). Most RCTs did not report the AEs in the title, abstract, or introduction, or report definitions of AEs and mention the methods for analyzing and presenting AEs. In 9 studies, the collecting and monitoring method for AEs involved retrospectively checking with the physician and/or participant, and the monitoring methods of 7 studies were not reported appropriately. Most studies reported the number of patients who stopped participating, as well as the specific denominator for the analysis of BVT-related AEs.

Table 3. Randomized controlled trials and randomized crossover trials reporting adverse events of bee venom therapy.

The meta-analysis of AE occurrence in the 4 RCTs assessing patients experiencing AEs showed that BVA increased the risk of AEs by 261% compared to the risk associated with normal saline control treatment (relative risk, 3.61; 95% CI [2.10, 6.20], Fig 2).

Fig 2. Relative risk of adverse events in randomized controlled trials with bee venom therapy and saline.


The aim of our systematic review was to summarize the evidence pertaining to BVT-related AEs by analyzing AE types and their prevalence in patients. We reviewed 145 studies, including 20 RCTs and randomized crossover studies, 79 audits and cohort studies, 33 single-case studies, and 13 case series. According to our findings, BVT can lead to AEs such as SRs, LLRs, LRs, SPs, and nonspecific reactions, some of which are serious.

In case studies and case series, we found that SRs comprised 51.72% of the AEs produced by bee venom. Moreover, the identified severe AEs included 14 cases of grade III SR and 1 case of grade IV SR (50.00% of the total SRs). We also found that there have been SAEs associated with BVT that urgently required subcutaneous adrenaline or steroid and oxygen therapy, with death occurring in 1 case [22] [51] [58]. Aside from SRs, AEs associated with BSA and BVA mainly include SPs such as granulomas and plaques, which may be attributable to persistent local inflammation caused by venomic components or from the remaining stinger at the site of cutaneous injection [29]. In contrast, SRs resulting from BVT are mainly derived from anaphylaxis, hypersensitivity, and late-onset reactions [3] [58].

In 46 audits and cohort studies of VIT, the median incidence of AEs was 28.87%, and SRs occurred in 681/4844 (14.06%) participants. These results suggest a more frequent AE incidence in comparison with that in previous systematic reviews of VIT, which reported SR incidences of 11.5 to 11.8% [159] [160]. Interestingly, some studies found a complete lack of AEs related to BVT and a corresponding lack of SRs, and some studies have shown minor AEs, but no serious SRs [60] [117,118] [134].

Skin tests allow practitioners to distinguish whether BVT is an appropriate intervention for particular patients. In most RCTs and randomized crossover trials with BSA and BVA, participants were included if they showed negative responses in skin tests, whereas participants were included in VIT case studies and case series if they showed positive responses in skin tests. This difference in the participants included in each type of study does not seem to be directly related to the AEs associated with BVT; negative venom skin test results are not always a guarantee of VIT safety [94]. However, serious AEs can occur as a result of BSA and BVA in patients with positive skins tests. There is a report of a young, healthy adult who was sensitized to bee venom through BSA, and who was later stung by a bee and developed severe, life-threatening anaphylaxis [161].

Venom concentration and the frequency of venom administration can influence the severity and rate of incidence of AEs resulting from BSA and BVA. Unfortunately, we could not analyze the effect of venom concentration and administration frequency on the severity and rate of incidence of AEs because only limited numbers of RCTs were included in this review.

With regard to the quality of reporting of AEs in RCTs, CONSORT items were generally not reported properly. Future RCTs with BVT must adopt the CONSORT AE reporting guidelines to ensure transparency and accuracy. When designing protocols, methods of AE assessment based on the CONSORT AE reporting guidelines should be suggested in detail.

AEs related to BVA or VIT have been reported in various studies, including surveys [8] [162] [163] and reviews [159] [160] [164] [165]. However, in this paper, we extensively reviewed all types of BVT (BSA, BVA, SBV, apitoxin injection, and VIT). We focused on the incidence of AEs in audit and cohort studies related to BVT, and sought to provide an overview of the many types of AEs that were reported in case studies and case series. We performed this investigation through a comprehensive search of the literature.

This review has some limitations. First, the heterogeneity of intervention in the reviewed articles was high; thus, the exact AE incidence and risk associated with the treatment methods could not be calculated. Second, although different venoms were used in different therapies (bee [family Apidae] venom was mainly used in BSA and BVA, whereas venom of both bees [family Apidae] and wasps [family Vespidae] was used in VIT), AEs from VIT were not classified in terms of the type of venom, treatment protocol (conventional VIT, cluster VIT, rush VIT, ultra-rush VIT, etc.), or phase (induction and maintenance).

While it is evident that BVA clearly increases the risk of AEs in comparison with normal saline, our review revealed that BSA and BVA are often implemented without a skin test, and also showed that patients have experienced SAEs that can be fatal after receiving BSA from unqualified personnel. Therefore, in order to enhance the safety of BVT, a skin test should be conducted before BVT is administered, and the venom should be administered only by qualified individuals [166].

Based on the results of this review, several suggestions can be made to support effective clinical practice and future clinical trials with BVT. In order to support responsible use of BVT, educational materials on the safety and efficacy of BVT should be made available for patients. Moreover, practitioners should be aware of the various AEs associated with BVT, establish clinical guidelines to minimize the development of AEs, and develop and implement strict criteria for monitoring AEs once they occur.


AEs related to BVT are not uncommon. Therefore, BVT practitioners should pay careful attention to the incidence of AEs and patterns of AE occurrence in their patients. Additionally, education and qualification of BVT practitioners should be ensured based on appropriate training programs and clinical guidelines for monitoring of AEs related to BVA and BSA. Furthermore, when reporting AEs in RCTs evaluating BVT, researchers should describe AEs in detail according to the CONSORT recommendation for harm data to ensure transparency and accuracy.

Supporting Information

S1 File. Search strategies for the electronic databases.



We thank the members of the Folk Medicine Team that was created for this study for their valuable input in planning the study.

Author Contributions

Conceived and designed the experiments: JHP THK JHL BKY SHL. Performed the experiments: JHP BKY. Wrote the paper: JHP THK. Extracted the data: JHP BKY. Monitored data collection: THK JHL.


  1. 1. Czarnetzki BM, Thiele T, Rosenbach T (1990) Evidence for leukotrienes in animal venoms. J Allergy Clin Immunol 85: 505–509. pmid:1968071
  2. 2. Alqutub AN, Masoodi I, Alsayari K, Alomair A (2011) Bee sting therapy-induced hepatotoxicity: A case report. World J Hepatol 3: 268–270. pmid:22059110
  3. 3. Bilò BM, Bonifazi F (2011) Hymenoptera venom immunotherapy. Immunotherapy 3: 229–246. pmid:21322761
  4. 4. Lee MS, Pittler MH, Shin BC, Kong JC, Ernst E (2008) Bee venom acupuncture for musculoskeletal pain: a review. J Pain 9: 289–297. pmid:18226968
  5. 5. Son DJ, Lee JW, Lee YH, Song HS, Lee CK, Hong JT (2007) Therapeutic application of anti-arthritis, pain-releasing, and anti-cancer effects of bee venom and its constituent compounds. Pharmacol Ther 115: 246–270. pmid:17555825
  6. 6. Valentine MD, Schuberth KC, Kagey-Sobotka A, Graft DF, Kwiterovich KA, Szklo M, et al. (1990) The value of immunotherapy with venom in children with allergy to insect stings. N Engl J Med 323: 1601–1603. pmid:2098016
  7. 7. Park JS, Lee MJ, Chung KH, Ko DK, Chung H (2013) Live bee acupuncture (Bong-Chim) dermatitis: dermatitis due to live bee acupuncture therapy in Korea. Int J Dermatol 52: 1519–1524. pmid:24134690
  8. 8. Adamic K, Zidarn M, Bajrovic N, Erzen R, Kopac P, Music E, et al. (2009) The local and systemic side-effects of venom and inhaled-allergen subcutaneous immunotherapy. Wiener klinische Wochenschrift 121: 357–360. pmid:19562302
  9. 9. Lockey RF, Turkeltaub PC, Olive ES, Hubbard JM, Baird-Warren IA, Bukantz SC, et al. (1990) The Hymenoptera venom study III: safety of venom immunotherapy. Journal of allergy and clinical immunology 86: 775–780. pmid:2229842
  10. 10. Mueller HL (1966) Diagnosis and treatment of insect sensitivity. J Asthma Res 3: 331–333. pmid:4380730
  11. 11. World Health Organization (2005) The use of the WHO-UMC system for standardized case causality assessment. Uppsala, Sweden. http://who-umcorg/Graphics/24734pdf.
  12. 12. Kim TH, Kim KH, Choi JY, Lee MS (2013) Adverse events related to cupping therapy in studies conducted in Korea: A systematic review. European Journal of Integrative Medicine. pmid:23795222
  13. 13. Bilo BM, Rueff F, Mosbech H, Bonifazi F, Oude-Elberink JN (2005) Diagnosis of Hymenoptera venom allergy. Allergy 60: 1339–1349. pmid:16197464
  14. 14. Turner LA, Singh K, Garritty C, Tsertsvadze A, Manheimer E, Wieland LS, et al. (2011) An evaluation of the completeness of safety reporting in reports of complementary and alternative medicine trials. BMC Complement Altern Med 11: 67. pmid:21859470
  15. 15. Ioannidis JP, Evans SJ, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, et al. (2004) Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 141: 781–788. pmid:15545678
  16. 16. An C-S, Kwon G-R, Lee J-S (2001) A clinical study on the cases of The pain shock patients after Korean bee-venom therapy. Journal of Pharmacopuncture 4: 109–117.
  17. 17. Bae EJ, Son SB, Seo SH, Son SW, Kim IH (2009) A case of foreign body granuloma with skin necrosis occurring after bee sting therapy. Korean Journal of Dermatology 47: 350–353.
  18. 18. Cheng YM, Ren XH (2004) Arrhythmia by bee sting acupuncture. Journal of Clinical Acupuncture and Moxibustion 20: 54.
  19. 19. Cho HJ, Choi GS, Kim JH, Sung JM, Ye YM, Park HS, et al. (2010) A case of serum sickness reaction caused by honeybee acupuncture. Korean Journal of Asthma, Allergy and Clinical Immunology 30: 325–328.
  20. 20. Herr H, Kim JH (1999) Eosinophilic granuloma induced by bee-sting therapy. Hanyang Medical Reviews 19: 159–162.
  21. 21. Huh SY, Yoo BG, Kim MJ, Kim JK, Kim KS (2008) Cerebral infarction after honey bee venom acupuncture. Journal of the Korean Geriatrics Society 12: 50–52.
  22. 22. Jung JW, Jeon EJ, Kim JW, Choi JC, Shin JW, Kim JY, et al. (2012) A fatal case of intravascular coagulation after bee sting acupuncture. Allergy Asthma Immunol Res 4: 107–109. pmid:22379607
  23. 23. Karapata A, Shumakov A (1961) A case of toxic pulmonary edema after the administration of bee venom in chronic nephritis. Klinicheskaia meditsina 39: 142–144. pmid:13885336
  24. 24. Kim DH, Kim MY, Park YM, Kim HO (2005) A case of delayed type skin reaction induced by bee venom acupuncture. Korean Journal of Dermatology 43: 1237–1240.
  25. 25. Kim JO, Shin BC, Hyun Lee Kim M, Chung JH (2007) Minimal change nephrotic syndrome after apitoxin therapy: a case report. Korean Journal of Nephrology 26: 736–739.
  26. 26. Kim JW, Yang I, Kim JW, Jung AY, Chung SY, Kim HD, et al. (2010) Radiologic findings of foreign body granuloma by the bee sting: a case report. Journal of the Korean Society of Radiology 62: 283–286.
  27. 27. Kim CW, Lee YH, Lee KH (2011) The case report of an anaphylaxis occurred when using sweet bee venom and common bee venom at the same time. Journal of Pharmacopuncture 14: 59–61.
  28. 28. Kwon KR, Kang KS, Lee KH, Lim CS, Jeong HS, Kwon HY, et al. (2009) Clinical observation of anaphylaxis after treated with Sweet BV. Journal of Korean Institute of Herbal Acupuncture 12: 85–90.
  29. 29. Lee C, Cho J, Yu H-J, Yang H, Park C, Park MH, et al. (1996) Bee-sting granulomas in the skin. Dermatology 193: 355–356. pmid:8993970
  30. 30. Lee SH, Sung KJ, Koh JK (1996) Foreign-body granuloma after honeybee acupuncture. Annals of Dermatology 8: 215–217.
  31. 31. Lee TW, Lee JA, Kim MK (2000) A case of anaphylaxis by bee venom acupuncture. Journal of Asthma, Allergy and Clinical Immunology 20: 551–552.
  32. 32. Lee S, Lee J, Choi Y, An J, Park M (2010) A case of foreign body granuloma following bee sting acupuncture on lipoma below frontalis(abstract). Korean journal of dermatology 48: 170–171.
  33. 33. Lee JS, Cho YS, Song KH, Hwang SR, Park J, Yun SK, et al. (2011) Foreign body granuloma following dried honey bee venom (Apitoxin Inj) injection. Korean Journal of Dermatology 49: 943–947.
  34. 34. Lee NR, Lee SY, Lee WS (2013) Granulomatous inflammation with chronic folliculitis as a complication of bee sting acupuncture. Indian Journal of Dermatology, Venereology, and Leprology 79: 554.
  35. 35. Li WY, Lin GH, Yin LH (2002) Investigation of anaphylaxis during bee sting acupuncture treatment. Chinese Journal of Natural Medicine 4: 163–164.
  36. 36. Li WY (2005) Investigation of interval bee sting acupuncture. Apiculture of China 56: 28–29.
  37. 37. Park JH, GU Kim J, Cha SH, Don Park S (1998) Eosinophilic foreign body granuloma after multiple self-administered bee stings. British journal of dermatology 139: 1102–1105. pmid:9990382
  38. 38. Park JH, Jung MK, Lee TK, Ahn MY, Bang CO (2000) A case of ischemic stroke following bee venom acupuncture. Journal of the Korean Neurological Association 18: 356–358.
  39. 39. Rhee DY, Lee HW, Chung WK, Chang SE, Lee MW, Choi JH, et al. (2009) Giant dermatofibroma with granular cell changes: side-effect of bee-venom acupuncture? Clin Exp Dermatol 34: e18–20. pmid:19486038
  40. 40. Rho YH, Woo JH, Choi SJ, Lee YH, Ji JD, Song GG. (2009) A new onset of systemic lupus erythematosus developed after bee venom therapy. Korean J Intern Med 24: 283–285. pmid:19721868
  41. 41. Shim WH, Park HJ, Kim HS, Chin HW, Kim SH, Ko HC, et al. (2011) Mybacterium chelonae infection occurring at the site of bee sting therapy. Korean Journal of Dermatology 49: 374–378.
  42. 42. Song HJ, Suh YJ, Yang YM, Jung JW, Lee YM, Suh CH, et al. (2002) Two cases of anaphylaxis due to bee venom acupuncture. Journal of Asthma, Allergy and Clinical Immunology 22: 481–486.
  43. 43. Veraldi S, Raiteri F, Caputo R, Alessi E (1995) Persistent nodular lesions caused by" bee-sting therapy". Acta dermato-venereologica 75: 161–162. pmid:7604655
  44. 44. Yoo MS, Ahn SK, Lee SH, Lee WS (1994) Contact urticaria due to bee sting therapy in a patient with chronic pain. Korean Journal of Dermatology 32: 895–898.
  45. 45. Yoon KS, Cho E, Kang JH, Lee H (2012) The clinical observation of bee venom hypersensitivity reaction after bee venom pharmacopuncture treatment. Research Institute of Korean Medicine, Taejon University 21: 117–124.
  46. 46. Youn H (2005) The clinical observation of anaphylaxis on bee-venom acupuncture. The Journal of Korean Acupuncture & Moxibustion Society 22: 179–188. pmid:25780715
  47. 47. Yu HJ, Lee CW, Yang HY, Kim JS, Kim YS (1998) Three cases of bee-sting granuloma. Korean Journal of Dermatology 36: 914–917.
  48. 48. Zhang JW, Shi DY, Wang LY, Liu RC, Zhang L (1995) Investigation of anaphylaxis by bee sting acupuncture in 9 case. Shanghai Journal of Acupuncture and Moxibustion 3: 126.
  49. 49. Zhong S, Zhou Z, Zhao Y, Luo Q, Ren H (2005) A case of subacute liver failure resulted from bee venom. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 13: 827, 831. pmid:16313726
  50. 50. Anfosso-Capra F, Philip-Joet F, Reynaud-Gaubert M, Arnaud A (1990) Occurrence of cold urticaria during venom desensitization. Dermatology 180: 276. pmid:2358109
  51. 51. Bousquet J, Menardo J, Velasquez G, Michel F (1988) Systemic reactions during maintenance immunotherapy with honey bee venom. Annals of allergy 61: 63–68. pmid:3061324
  52. 52. De Bandt M, Atassi-Dumont M, Kahn M, Herman D (1997) Serum sickness after wasp venom immunotherapy: clinical and biological study. The Journal of rheumatology 24: 1195–1197. pmid:9195533
  53. 53. Eming SA, Theile-Ochel S, Casper C, Krieg T, Scharffetter-Kochanek K, Hunzelmann N. (2004) Panniculitis induced by specific venom immunotherapy. Dermatology 209: 62–63. pmid:15237271
  54. 54. Karakurt F, Kargili A, Bozkurt B, Kasapoglu B, Ikizek M (2010) Uterine contractions: an unusual side effect of venom immunotherapy. J Investig Allergol Clin Immunol 20: 431–432. pmid:20945611
  55. 55. Lyanga J, McPHILLIPS-FEENER S, Warrington R (1982) Transient bradycardia during vespid venom immunotherapy. Clinical & Experimental Allergy 12: 91–93.
  56. 56. Nemat K, Gahr M, Reuner U (2011) Neuralgic amyotrophy associated with venom immunotherapy. Allergologie 34: 68.
  57. 57. Pijak M, Csibova V (2011) Hepatitis B reactivation complicated with nephrotic syndrome in association with venom immunotherapy-Need for preemptive treatment? Hepatology International 5: 104.
  58. 58. Reisman R (1988) Late onset reactions following venom immunotherapy and venom skin tests. Annals of allergy 61: 383–387. pmid:3189964
  59. 59. Yalcin A, Bisgin A, Akman A, Erdogan G, Çiftcioglu M, Yegin O. (2012) Jessner lymphocytic infiltrate as a side effect of bee venom immunotherapy. Journal of investigational allergology & clinical immunology 22: 308. pmid:23721594
  60. 60. Castro HJ, Mendez-Inocencio JI, Omidvar B, Omidvar J, Santilli J, Nielsen HS, et al. (2005) A phase I study of the safety of honeybee venom extract as a possible treatment for patients with progressive forms of multiple sclerosis. Allergy and asthma proceedings 26: 470–476. pmid:16541972
  61. 61. Choi SW, Choi SU, Oh SJ (2010) A clinical report of localized itching after treatment with sweet bee venom. Journal of Pharmacopuncture 13: 103–108.
  62. 62. Gao PX (2011) Bee acupuncture treatment of 250 patients with refractory peripheral facial paralysis and nursing of patients. Contemporary Nurse: 117–119.
  63. 63. Hwang Y, Lee B (2000) Clinical study of anaphylaxis on bee venom acupuncture. The Journal of Korean Acupuncture & Moxibustion Society 17: 149–159. pmid:25780715
  64. 64. Jung DJ, Lee HG, Choi YM, Song BY, Yook TH, Kim JU. (2013) The clinical study on 130 cases with sweet bee venom treatment. The Acupuncture 30: 211–217.
  65. 65. Kwon G, Koh H (2000) The clinical observation of immune response by Korean bee venom therapy. The Journal of Korean Acupuncture & Moxibustion Society 17: 169–174. pmid:25780715
  66. 66. Li WY, Deng JF, Lai XE, Lin GH (1995) Observation of anaphylaxis by bee sting therapy. Journal of Bee Venom 7: 3–5.
  67. 67. Liu WQ, Wu HZ (1993) Bee venom acupuncture therapy for chronic hepatitis B in 32 cases. Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases 3: 31–32.
  68. 68. Ma H, Chang WZ (2008) Clinical observation of simultaneous treatment morphine sulfate controlled-release tablets and apitoxin injection for cancer pain. Jilin Medical Journal 29: 1914–1915.
  69. 69. Tang T, Lei Y, Zhao MQ (2004) Treatment of 468 osteoarthritis patients by acupoint injection of apisin and fengtongning. Shanghai Journal of Acupuncture and Moxibustion 22: 21–22.
  70. 70. Wen WQ, Huang SG, Wang RY (2003) Bee sting acupuncture for undifferentiated connective tissue diseases in 40 cases. Journal of Guangzhou University of Traditional Chinese Medicine 20: 221–223.
  71. 71. Xiao X, Zhao B, Li W (2013) Analysis on the pattern of edema in initial patients treated by apitherapy. Apiculture of China 64: 53–55.
  72. 72. Yoon J, Jeon JH, Lee YW, Cho CK, Kwon KR, Shin JE, et al. (2012) Sweet bee venom pharmacopuncture for chemotherapy-induced peripheral neuropathy. J Acupunct Meridian Stud 5: 156–165. pmid:22898064
  73. 73. Yu XJ (2006) Cases of parallel bee acupuncture and bee products treatment for rare disease. Apiculture of China 57: 27–28.
  74. 74. Zhang JL, Liu XD, Ye LH, Zhang P (2010) Clinical observation on toxicity of bee venom. Zhejiang Journal of Traditional Chinese Medicine 45: 849–850.
  75. 75. Zhou RY, Tan N, Huang SG (2009) Parallel kidney tonic decoction and bee venom therapy for ankylosing spondylitis in 40 cases. Guiding Journal of Traditional Chinese Medicine and Pharmacy 15: 40–41.
  76. 76. Aguilar CM, Pasadas FG (1999) Immunotherapy with Hymenoptera venoms. Safety of a cluster schedule. Alergologia et Inmunologia Clinica 14: 315–321.
  77. 77. Alessandrini AE, Berra D, Rizzini FL, Mauro M, Melchiorre A, Rossi F, et al. (2006) Flexible approaches in the design of subcutaneous immunotherapy protocols for Hymenoptera venom allergy. Annals of Allergy, Asthma & Immunology 97: 92–97.
  78. 78. Anguita Carazo J, Gutierrez Fernandez D, Fernandez Melendez S, Saenz de San Pedro Morera B, Munoz Munoz M, Foncubierta Fernandez A. (2011) Safety and tolerability of a venom immunotherapy protocol in a retrospective study. Allergy: European Journal of Allergy and Clinical Immunology 66: 436. pmid:21284653
  79. 79. Bemanian MH, Farhoudi A, Pourpak Z, Gharagozlou M, Movahedi M, Nabavi M, et al. (2007) Systemic and local reactions of bee venom immunotherapy in Iran. Iranian Journal of Allergy, Asthma and Immunology 6: 203–206. pmid:18094443
  80. 80. Bernstein DI, Mittman RJ, Kagen SL, Korbee L, Enrione M, Bernstein IL. (1989) Clinical and immunologic studies of rapid venom immunotherapy in Hymenoptera-sensitive patients. Journal of allergy and clinical immunology 84: 951–959. pmid:2480972
  81. 81. Bernstein JA, Kagen SL, Bernstein DI, Bernstein IL (1994) Rapid venom immunotherapy is safe for routine use in the treatment of patients with Hymenoptera anaphylaxis. Annals of allergy 73: 423–428. pmid:7978535
  82. 82. Birnbaum J, Charpin D, Vervloet D (1993) Rapid Hymenoptera venom immunotherapy: comparative safety of three protocols. Clinical & Experimental Allergy 23: 226–230.
  83. 83. Birnbaum J, Ramadour M, Magnan A, Vervloet D (2003) Hymenoptera ultra-rush venom immunotherapy (210 min): a safety study and risk factors. Clinical & Experimental Allergy 33: 58–64.
  84. 84. Bonadonna P, Zanotti R, Caruso B, Castellani L, Perbellini O, Colarossi S, et al. (2008) Allergen specific immunotherapy is safe and effective in patients with systemic mastocytosis and Hymenoptera allergy. J Allergy Clin Immunol 121: 256–257. pmid:18206512
  85. 85. Bonadonna P, Gonzalez-De-Olano D, Zanotti R, Riccio A, De Ferrari L, Lombardo C, et al. (2013) Venom immunotherapy in patients with clonal mast cell disorders: efficacy, safety, and practical considerations. The Journal of Allergy and Clinical Immunology: In Practice 1: 474–478. pmid:24565619
  86. 86. Brehler R, Wolf H, Kütting B, Schnitker J, Luger T (2000) Safety of a two-day ultrarush insect venom immunotherapy protocol in comparison with protocols of longer duration and involving a larger number of injections. Journal of Allergy and Clinical Immunology 105: 1231–1235. pmid:10856159
  87. 87. Bucher C, Schwager S, Schmid-Grendelmeier P, Wuthrich B (2003) Safety of ultrarush-hyposensitization with honey bee and yellow jacket venom. Allergo Journal 12: S62–63.
  88. 88. Cadario G, Marengo F, Ranghino E, Rossi R, Gatti B, Cantone R, et al. (2004) Higher frequency of early local side effects with aqueous versus depot immunotherapy for Hymenoptera venom allergy. J Investig Allergol Clin Immunol 14: 127–133. pmid:15301302
  89. 89. Calaforra S, Ibanez E, Diaz M, Colomer N, Giner A, Almero R, et al. (2009) Tolerance of a cluster immunotherapy protocol for hymenoptera venom. Allergy 64: 455.
  90. 90. Carballada F, Martín S, Boquete M (2002) High efficacy and absence of severe systemic reactions after venom immunotherapy. Journal of investigational allergology & clinical immunology 13: 43–49. pmid:23721594
  91. 91. Carballada González FJ, Crehuet Almirall M, Manjón Herrero A, De la Torre F, Boquete París M (2009) Hymenoptera venom allergy: characteristics, tolerance and efficacy of immunotherapy in the paediatric population. Allergologia et immunopathologia 37: 111–115. pmid:19769842
  92. 92. Catalá M, Gómez A, Ollo B, Gurpegui M, Talens M (2009) Safety of Hymenopteran venoms immunotherapy in a cluster schedule. A nursing perspective. Anales del sistema sanitario de Navarra 32: 409–412. pmid:20094101
  93. 93. Caubet JC, Eigenmann P (2008) Late side-effects during systemic immunotherapy in children. Allergy 63: 1561–1562. pmid:18925895
  94. 94. Cavallucci E, Ramondo S, Renzetti A, Turi M, Di Claudio F, Braga M, et al. (2010) Maintenance venom immunotherapy administered at a 3-month interval preserves safety and efficacy and improves adherence. J Investig Allergol Clin Immunol 20: 63–68. pmid:20232775
  95. 95. de Jong N, Vermeulen A, de Groot H (1999) Allergy to bumblebee venom. III. Immunotherapy follow-up study (safety and efficacy) in patients with occupational bumblebee-venom anaphylaxis. Allergy 54: 980–984. pmid:10505462
  96. 96. Dursun A, Sin B, Oner F, Misirligil Z (2006) The safety of allergen immunotherapy (IT) in Turkey. Journal of investigational allergology and clinical immunology 16: 123–128. pmid:16689186
  97. 97. Eben R, Ganeva R, Przybilla B, Rueff F (2010) Safety of increased maintenance dose in patients on hymenoptera venom immunotherapy. Allergy 65: 101. pmid:20439229
  98. 98. Gastaminza G, Algorta J, Audicana M, Etxenagusia M, Fernandez E, Muñoz D. (2003) Systemic reactions to immunotherapy: influence of composition and manufacturer. Clinical & Experimental Allergy 33: 470–474.
  99. 99. Goldberg A, Yogev A, Confino-Cohen R (2011) Three days rush venom immunotherapy in bee allergy: safe, inexpensive and instantaneously effective. International archives of allergy and immunology 156: 90–98. pmid:21447964
  100. 100. Golden DB, Valentine MD, Kagey-Sobotka A, Lichtenstein LM (1980) Regimens of Hymenoptera venom immunotherapy. Ann Intern Med 92: 620–624. pmid:7387002
  101. 101. Golub J, Kaplan S, Mascia A (1984) Stinging insect hypersensitivity. Safety and efficacy of venom immunotherapy. New York state journal of medicine 84: 66–68. pmid:6583559
  102. 102. Gonzalez de Olano D, Alvarez-Twose I, Esteban-Lopez MI, Sanchez-Munoz L, de Durana MD, Vega A, et al. (2008) Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis. J Allergy Clin Immunol 121: 519–526. pmid:18177694
  103. 103. Gorska L, Chelminska M, Kuziemski K, Skrzypski M, Niedoszytko M, Damps-Konstanska I, et al. (2008) Analysis of safety, risk factors and pretreatment methods during rush hymenoptera venom immunotherapy. International archives of allergy and immunology 147: 241–245. pmid:18594155
  104. 104. Hirata H, Asakura T, Arima M, Cheng G, Honda K, Fukushima F, et al. (2003) Efficacy and safety of rush immunotherapy in patients with Hymenoptera allergy in Japan. Asian Pac J Allergy Immunol 21: 89–94. pmid:14629126
  105. 105. Kalogeromitros D, Makris M, Koti I, Chliva C, Mellios A, Avgerinou G, et al. (2010) A simple 3-day "rush" venom immunotherapy protocol: documentation of safety. Allergol Immunopathol (Madr) 38: 69–73. pmid:19853357
  106. 106. Kerddonfak S, Manuyakorn W, Kamchaisatian W, Sasisakulporn C, Teawsomboonkit W, Benjaponpitak S. (2009) Rush Hymenoptera Venom Immunotherapy in Thai Children. Journal of Allergy and Clinical Immunology 123: S242.
  107. 107. Kohli-Wiesner A, Stahlberger L, Bieli C, Stricker T, Lauener R (2012) Induction of specific immunotherapy with hymenoptera venoms using ultrarush regimen in children: safety and tolerance. J Allergy (Cairo) 2012: 790910. pmid:21804830
  108. 108. Kopae P, Zidarn M, Bajrovic N, Erzen R, Adamie K, Kosnik M, et al. (2009) Safety of specific immunotherapy using ultra-rush 150-min induction scheme in hymenoptera venom allergy. Allergy 64: 455.
  109. 109. Lata J, Specjalski K, Kolaczkowska M, Chelminska M, Niedoszytko M, Jassem E, et al. (2005) Side effects of specific immunotherapy in patients with hymenoptera venom allergy. Pneumonol Alergol Pol 73: 260–263. pmid:16989163
  110. 110. Laurent J, Smiejan JM, Bloch-Morot E, Herman D (1997) Safety of Hymenoptera venom rush immunotherapy. Allergy 52: 94–96. pmid:9062635
  111. 111. Lee H, Roediger C, Bauer A, Zuberbier T, Worm M (2006) Prospective safety analysis of an ultrarush specific immunotherapy in adults with wasp venom allergy. Allergy 61: 1237–1238. pmid:16942578
  112. 112. Marques L, Compaired J, Gala G, Varela S, Garcia M, Justicia J. (2010) Safety and effectiveness of hymenoptera venom immunotherapy, in actual clinical practice. Allergy 65: 101. pmid:20439229
  113. 113. Mellerup MT, Hahn GW, Poulsen LK, Malling H (2000) Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment. Clin Exp Allergy 30: 1423–1429. pmid:10998019
  114. 114. Mingomataj E, Priftanji A, Qirko E, Dinh QT, Fischer A, Peiser C, et al. (2002) Specific immunotherapy in Albanian patients with anaphylaxis to hymenoptera venoms. BMC Dermatol 2: 11. pmid:12201901
  115. 115. Mosbech H, Muller U (2000) Side-effects of insect venom immunotherapy: results from an EAACI multicenter study. European Academy of Allergology and Clinical Immunology. Allergy 55: 1005–1010. pmid:11097308
  116. 116. Muller U, Helbling A, Berchtold E (1992) Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J Allergy Clin Immunol 89: 529–535. pmid:1740583
  117. 117. Nagai Y, Oyama N, Hattori T, Ishikawa O, Tamura M (2004) A clinical study of 245 Japanese patients with bee sting and two cases administrated rush hymenoptera venom immunotherapy. The Kitakanto medical journal 54: 297–300.
  118. 118. Nataf P, Guinnepain MT, Herman D (1984) Rush venom immunotherapy: a 3-day programme for hymenoptera sting allergy. Clin Allergy 14: 269–275. pmid:6610502
  119. 119. Pasaoglu G, Sin BA, Misirligil Z (2006) Rush hymenoptera venom immunotherapy is efficacious and safe. J Investig Allergol Clin Immunol 16: 232–238. pmid:16889280
  120. 120. Poli F, Longo G, Parmiani S (2001) The safety and efficacy of immunotherapy with aluminum hydroxide-adsorbed venom extract of Vespula spp. An open, retrospective study. Allergol Immunopathol (Madr) 29: 191–196. pmid:11720652
  121. 121. Quercia O, Rafanelli S, Puccinelli P, Stefanini GF (2001) The safety of cluster immunotherapy with aluminium hydroxide-adsorbed honey bee venom extract. J Investig Allergol Clin Immunol 11: 27–33. pmid:11436967
  122. 122. Quercia O, Emiliani F, Pecora S, Burastero SE, Stefanini GF (2006) Efficacy, safety, and modulation of immunologic markers by immunotherapy with honeybee venom: comparison of standardized quality depot versus aqueous extract. Allergy Asthma Proc 27: 151–158. pmid:16724636
  123. 123. Ramirez D, Londono S, Evans R 3rd (1981) Adverse reactions to venom immunotherapy. Annals of allergy 47: 435–439. pmid:7325415
  124. 124. Rocklin RE, Alfano N, Sabotka AK, Rosenwasser LJ, Findlay SR (1962) Low incidence of systemic reactions during venom immunotherapy. Journal of Allergy and Clinical Immunology 69: 125.
  125. 125. Roll A, Hofbauer G, Ballmer-Weber BK, Schmid-Grendelmeier P (2006) Safety of specific immunotherapy using a four-hour ultra-rush induction scheme in bee and wasp allergy. J Investig Allergol Clin Immunol 16: 79–85. pmid:16689180
  126. 126. Roumana A, Pitsios C, Vartholomaios S, Kompoti E, Kontou-Fili K (2009) The safety of initiating Hymenoptera immunotherapy at 1 mug of venom extract. Journal of allergy and clinical immunology 124: 379–381. pmid:19560804
  127. 127. Ruëff F, Reissig J, Przybilla B (1997) Side effects of rush hyposensitization with hymenoptera venoms. Allergo Journal 6: S59–S64.
  128. 128. Rueff F, Wolf H, Schnitker J, Ring J, Przybilla B (2004) Specific immunotherapy in honeybee venom allergy: a comparative study using aqueous and aluminium hydroxide adsorbed preparations. Allergy 59: 589–595. pmid:15147443
  129. 129. Sanchez-Machin I, Moreno C, Gonzalez R, Iglesias-Souto J, Perez E, Matheu V. (2010) Safety of a 2-visit cluster schedule of venom immunotherapy in outpatients at risk of life-threatening anaphylaxis. J Investig Allergol Clin Immunol 20: 91–92. pmid:20232782
  130. 130. Sanchez-Morillas L, Reano Martos M, Rodriguez Mosquera M, Iglesias Cadarso A, Dominguez Lazaro AR (2005) Safety of rush immunotherapy with Hymenoptera venom. Allergol Immunopathol (Madr) 33: 224–227. pmid:16045862
  131. 131. Schiavino D, Nucera E, Pollastrini E, De Pasquale T, Buonomo A, Bartolozzi F, et al. (2004) Specific ultrarush desensitization in Hymenoptera venom-allergic patients. Ann Allergy Asthma Immunol 92: 409–413. pmid:15104191
  132. 132. Sporcic Z, Milicic A, Tadic D, Subotic M, Parabucki TD, Kuzmanovic PD, et al. (2009) Safety of hymenoptera venom immunotherapy: our experience. Allergy 64: 342.
  133. 133. Sturm G, Kränke B, Rudolph C, Aberer W (2002) Rush Hymenoptera venom immunotherapy: A safe and practical protocol for high-risk patients. Journal of Allergy and Clinical Immunology 110: 928–933. pmid:12464961
  134. 134. Tarhini H, Knani J, Michel FB, Bousquet J (1992) Safety of venom immunotherapy administered by a cluster schedule. Journal of allergy and clinical immunology 89: 1198–1199. pmid:1607554
  135. 135. Thurnheer U, Muller U, Stoller R, Lanner A, Hoigne R (1983) Venom immunotherapy in hymenoptera sting allergy. Comparison of rush and conventional hyposensitization and observations during long-term treatment. Allergy 38: 465–475. pmid:6638413
  136. 136. Wenzel J, Meissner-Kraemer M, Bauer R, Bieber T, Gerdsen R (2005) Answer to the letter of Brockow et al. concerning our article 'safety of rush insect venom immunotherapy. Results of a retrospective study in 178 patients'. Allergy 60: 127. pmid:15575945
  137. 137. Westall GP, Thien FC, Czarny D, O'Hehir RE, Douglas JA (2001) Adverse events associated with rush hymenoptera venom immunotherapy. Med J Aust 174: 227–230. pmid:11280693
  138. 138. Youlten LJ, Atkinson BA, Lee TH (1995) The incidence and nature of adverse reactions to injection immunotherapy in bee and wasp venom allergy. Clin Exp Allergy 25: 159–165. pmid:7750008
  139. 139. Cho SY, Shim SR, Rhee HY, Park HJ, Jung WS, Moon SK, et al. (2012) Effectiveness of acupuncture and bee venom acupuncture in idiopathic Parkinson's disease. Parkinsonism Relat Disord 18: 948–952. pmid:22632852
  140. 140. Cho SY, Park JY, Jung WS, Moon SK, Park JM, Ko CN, et al. (2013) Bee venom acupuncture point injection for central post stroke pain: a preliminary single-blind randomized controlled trial. Complement Ther Med 21: 155–157. pmid:23642945
  141. 141. Deng M, Zhang WN (2011) Clinical observation of bee sting acupuncture therapy for rheumatoid arthritis in 20 cases. Guiding Journal of Traditional Chinese Medicine and Pharmacy 17: 71–73.
  142. 142. Gwak JY, Cho SY, Shin AS, Lee IW, Kim NH, Kim HM, et al. (2009) Efficacy of bee-venom acupuncture on central post stroke pain: single-blind randomized controlled trial. The Journal of Korean Acupuncture and Moxibustion Society 26: 205–214.
  143. 143. Kim K, Song H (2005) A randomized controlled double blinding study of bee venom acupuncture therapy on sprain of c-spine. J Korean Acupunct Moxibustion Soc 22: 189–195.
  144. 144. Ko C, Min I, Park S, Jung W, Moon S, Park J, et al. (2007) Effectiveness of bee venom acupuncture on shoulder pain after stroke. J Korean Oriental Med 28: 11–24.
  145. 145. Koh PS, Seo BK, Cho NS, Park HS, Park DS, Baek YH. (2013) Clinical effectiveness of bee venom acupuncture and physiotherapy in the treatment of adhesive capsulitis: a randomized controlled trial. J Shoulder Elbow Surg 22: 1053–1062. pmid:23352187
  146. 146. Ku JY, Lee KH, Cho SW, Lee SC, Youn HM, Jang KJ, et al. (2010) Comparison of the effects between sweet bee venom pharmacopuncture and scolopendrid pharmacopuncture on carpal tunnel syndrome (randomized, controlled clinical trial). Journal of Pharmacopuncture 13: 75–89.
  147. 147. Lee S, Hong S, Kim S, Yang H, Lee J, Choi D, et al. (2003) Randomized controlled double blind study of bee venom therapy on rheumatoid arthritis. J Kor Acu Mox Soc 20: 80–88.
  148. 148. Noh JH, Park JA, Cho SW, Youn HM, Jang KJ, Song CH, et al. (2010) Effect of bee-venom acupuncture on upper limb spasticity of stroke patients. The Journal of Korean Acupuncture and Moxibustion Society 27: 115–125.
  149. 149. Rong L, Lun X (2002) Clinical observation of bee sting acupuncture for rheumatoid arthritis. Journal of External Therapy of TCM 11: 14–15.
  150. 150. Shin BC, Kong JC, Park TY, Yang CY, Kang KW, Choi SM, et al. (2012) Bee venom acupuncture for chronic low back pain: a randomised, sham-controlled, triple-blind clinical trial. European Journal of Integrative Medicine 4: e271–e280.
  151. 151. Song HS (2005) The effect of bee venom acupuncture(BVA) on acute ankle sprain: a randomized controlled trial and double blinding-pilot study. Journal of Pharmacopuncture 8: 11–16.
  152. 152. Wen WQ, Huang SG, Chen H, Tan N, Zhou RY, Zhu HJ. (2011) Bee-acupuncture based on Midnight-Noon and Ebb-Flow doctrine for ankylosing spondylitis. Journal of Anhui Traditional Chinese Medical College 30: 40–43.
  153. 153. Wen WQ, Huang SG, Chen H, Tan N, Zhou RY, Zhu HJ. (2012) Effects and mechanism of bee-venom-acupuncture based on Midnight-Noon and Ebb-Flow doctrine on ankylosing spondylitis. Journal of Traditional Chinese Medicine University of Hunan 32: 67–71.
  154. 154. Wesselius T, Heersema D, Mostert J, Heerings M, Admiraal-Behloul F, Talebian A, et al. (2005) A randomized crossover study of bee sting therapy for multiple sclerosis. Neurology 65: 1764–1768. pmid:16221950
  155. 155. Won CH, Choi ES, Hong SS (1999) Efficacy of bee venom injection for osteoarthritis patients. The Journal of the Korean Rheumatism Association 6: 218–226.
  156. 156. Yoo H, Kim J (2008) The effect of sweet bee venom pharmacopuncture (SBVP) on cancer-related pain: a randomized controlled trial and double blinded-pilot study. J Korean Pharmacopuncture Institute 11: 21–29.
  157. 157. Oude Elberink JNG, de Monchy JGR, van der Heide S, Guyatt GH, Dubois AEJ (2002) Venom immunotherapy improves health-related quality of life in patients allergic to yellow jacket venom. Journal of Allergy and Clinical Immunology 110: 174–182. pmid:12110838
  158. 158. Oude Elberink JN, van der Heide S, Guyatt GH, Dubois AE (2006) Analysis of the burden of treatment in patients receiving an EpiPen for yellow jacket anaphylaxis. J Allergy Clin Immunol 118: 699–704. pmid:16950290
  159. 159. Boyle RJ, Elremeli M, Hockenhull J, Cherry MG, Bulsara MK, Daniels M, et al. (2012) Venom immunotherapy for preventing allergic reactions to insect stings. Cochrane Database Syst Rev 10: Cd008838. pmid:23076950
  160. 160. Incorvaia C, Frati F, Dell'Albani I, Robino A, Cattaneo E, Mauro M, et al. (2011) Safety of hymenoptera venom immunotherapy: a systematic review. Expert Opin Pharmacother 12: 2527–2532. pmid:21883032
  161. 161. Lee SH, Kang HR, Kim JH, Park SH, Kim CH, Hwang YI, et al. (2008) A fatal case of bee venom anaphylaxis to bee sting after repeated honeybee acupuncture. Korean Journal of Asthma, Allergy and Clinical Immunology 28: 313–316.
  162. 162. Golden DB, Kagey-Sobotka A, Lichtenstein LM (2000) Survey of patients after discontinuing venom immunotherapy. J Allergy Clin Immunol 105: 385–390. pmid:10669863
  163. 163. Schwartz HJ, Golden DB, Lockey RF (1990) Venom immunotherapy in the Hymenoptera-allergic pregnant patient. J Allergy Clin Immunol 85: 709–712. pmid:2324411
  164. 164. Yi W-S (2014) Adverse events of bee venom acupuncture: a systematic review. Seoul: Graduate School of Kyung Hee University.
  165. 165. Ross RN, Nelson HS, Finegold I (2000) Effectiveness of specific immunotherapy in the treatment of hymenoptera venom hypersensitivity: a meta-analysis. Clin Ther 22: 351–358. pmid:10963289
  166. 166. Liccardi G, D'Amato G, Canonica GW, Salzillo A, Piccolo A, Passalacqua G, et al. (2006) Systemic reactions from skin testing: literature review. J Investig Allergol Clin Immunol 16: 75–78. pmid:16689179